Kevin W. Christensen, PhD is a director in BRG’s Washington, DC office. Dr. Christensen specializes in antitrust and competition policy, damages analysis, and public policy, which he often applies in the context of the pharmaceutical industry.

He regularly works on class action litigation matters to address questions of class certification and estimation of classwide damages. He has submitted expert reports to the US District Court for the District of Columbia, US District Court for the Eastern District of Virginia, state courts, and regulatory agencies. Dr. Christensen has provided deposition testimony in state and federal courts. Additionally, he has written white papers submitted to the State of Florida’s Department of Transportation and drafted portions of new product applications submitted to the US Food and Drug Administration (FDA).

Dr. Christensen has been involved in competition and antitrust matters that included price fixing, monopoly and attempted monopoly, monopsony and attempted monopsony, market allocation, raising rivals costs, and tying and bundling allegations. He also has worked on several mergers and acquisitions and nonpublic investigations by federal agencies, estimated economic damages in antitrust and false advertising litigations, and provided testimony on economic damages resulting from bribery. His disputes and investigations work spans industries including oil and gas, pharmaceutical, biotechnology, medical device, banking, automobile finance, wholesale distribution, transportation, consumer packaged goods (CPG), agriculture, building materials, tourism, and gaming.

In addition to his litigation practice, Dr. Christensen is regularly engaged on matters of public policy. In this context, Dr. Christensen has estimated the economic and tax revenue impact of proposed infrastructure investments or regulatory changes. He has also worked on matters involving the economic and tax implications of ballot initiatives.

Dr. Christensen holds a PhD and MA from the University of Florida and a BS from James Madison University, all in economics. Between 2018 and 2022, he was selected by Global Competition Review for its Who’s Who Legal: Competition – Future Leaders publication, which highlights experts in the field of competition economics under the age of forty-five. In 2023, Dr. Christensen was included in Who’s Who Legal: Competition – Economists and Consulting Experts – Economics publications. From 2011 to 2022, he was on the board of editors for the Antitrust Source, an online publication from the American Bar Association’s Section of Antitrust Law. From 2018 to 2021, Dr. Christensen was a member of the James Madison University Economics Department Executive Advisory Board. He served as chair of the Advisory Board for two years. Currently, he is on the board of directors for RxPartnership, a part of the healthcare safety net that provides affordable brand and generic medications to low-income, uninsured Virginians.

Employment History

Finance Scholars Group
Consulting economist

Edgeworth Economics
Vice president
2010 – 2012

The CapAnalysis Group, LLC
2006 – 2010

Ernst & Young, LLP
1998 – 2001

Professional Affiliations

American Economic Association

National Association of Business Economists

American Bar Association
Associate Member

Areas of Expertise


University of Florida
PhD, Economics, 2006
MA, Economics, 2004

James Madison University
BS, Economics, 1998


Who’s Who Legal: Who’s Who Legal: Competition Future Leaders, Economists 2020

“Kevin Christensen is ‘held in very high regard’ for his top-tier economic research across an array of industries.”